Latest Breaking News On - Label expansion - Page 1 : comparemela.com

Glucagon Market Poised for Remarkable Growth, to Surpass USD 553 3 Million by 2033, Enabling 6 7% |

Glucagon Market Poised for Remarkable Growth, to Surpass USD 553 3 Million by 2033, Enabling 6 7% |
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesLawrence johnNovo nordiskAsia pacificZealand pharmaDrug stores retail pharmaciesAmphastar pharmaceuticals incRoute of administrationPrudour pvt ltdFresenius se coXeris biopharma holdings incDevelopment of novel delivery systemsTaj pharmaceuticals limited indiaUnited biotechp limited indiaGlobal glucagon market

Intra-Cellular Therapies Is On Fire

Intra-Cellular Therapies Is On Fire
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

United statesKen lundowRisperidone risperdalProduct patentAmerican psychiatric associationCellular therapiesMajor depressive disorderLabel expansionAccount managerBristol myers squibbNew chemical entityBase product patentCrystal formEli lillyWall street

Approved Drug for Skin Condition Shown Safe at Higher Dose

Approved Drug for Skin Condition Shown Safe at Higher Dose

United statesJonathan aschoffDrug administrationBiofrontera incLabel expansionInvestor ideasUnapproved drugOr skin condition

Picard Medical and its Subsidiary, SynCardia Systems, a Pioneer in Total Artificial Heart Technology, to Become a Publicly Traded Company via Merger with Altitude Acquisition Corp

SynCardia Manufactures and Distributes the First-and-Only Commercially Available and FDA Approved Total Artificial Heart SynCardia is Entering a Rapid Growth Phase Supported by New Product. | June 18, 2023

United statesGary teplisMatthew hauschRichard fangAltitude acquisition corpTheir existing equity holdingsEuropean unionPicard medical holdings incSyncardia systemsExchange commissionPicard medical incPerimeter center terrace suiteInternational growthWhite caseWinston strawnProduct development

G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib

G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San antonioUnited statesRebecca levinedirectorRaj malikExchange commissionTherapeutics incCorporate communicationsResearch triangle parkInvestor relations corporate communicationsPivotal phaseColorectal cancer expectedLabel expansionClinical trialsData readoutsEvaluate trilaciclib on target effectsEnhanced immune function